A Phase I Clinical Trial in 18-60 Adults

Condition:   COVID-19 Intervention:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Sponsors:   CanSino Biologics Inc.;   Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China;   Jiangsu Province Centers for Disease Control and Prevention;   Hubei Provincial Center for Disease Control and Prevention;   Tongji Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Discussions with the FDA are ongoing to define the required data set for filing Janssen’s Ebola vaccine regimen under the FDA’s Animal Rule licensure pathway. About Janssen’s Ebola Vaccine Regimen The Janssen investigational preventive Ebola vaccine regimen (Ad26.ZEBOV, MVA-BN-Filo) utilizes a viral vector strategy in which viruses – in this case adenovirus serotype 26 (Ad26) and Modified Vaccinia Virus Ankara (MVA) – are genetically modified so that they cannot replicate in human cells. In addition, these vectors are modified to safely carry the genetic code of an Ebola virus protein in order...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COVID-19 Interventions:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector);   Biological: Placebo Sponsors:   CanSino Biologics Inc.;   Beijing Institute of Biotechnology;   Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
BOSTON (CBS) – Two Boston hospitals are teaming up in the race to find a cure for the coronavirus pandemic. Researchers at Massachusetts Eye and Ear and Massachusetts General Hospital are working together to develop a vaccine using a unique gene-based strategy. Their research is using what’s called AAV technology, or Adeno-Associated-Virus technology, in hopes of stimulating the immune system to fight SARS-CoV-2 – the virus responsible for COVID-19. “We’re taking a virus called AAV, that’s harmless and has been engineered to be harmless, and we’re using it essentially as a delivery...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Syndicated CBSN Boston Syndicated Local Coronavirus Mass Eye And Ear Mass General Hospital Source Type: news
Microneedle arrays (MNAs) are a promising way of delivering vaccines into the body. They are nearly pain-free and can penetrate a substantial portion of the skin, which is considered an excellent place to inject vaccines because of the skin’s s...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Public Health Source Type: blogs
Condition:   COVID-19 Interventions:   Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);   Other: Placebo Sponsors:   Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China;   CanSino Biologics Inc.;   Jiangsu Province Centers for Disease Control and Prevention;   Hubei Provincial Center for Disease Control and Prevention Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Adenoviruses | Biotechnology | Centers for Disease Control and Prevention (CDC) | China Health | Clinical Trials | Coronavirus | COVID-19 | Hospitals | Research | Vaccines